# A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

> **NCT05254002** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 1664 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Chronic Kidney Disease

## Interventions

- **DRUG:** Finerenone (BAY94-8862 ) 10 mg
- **DRUG:** Empagliflozin
- **DRUG:** Empagliflozin Placebo
- **DRUG:** Finerenone (BAY94-8862 ) 20 mg
- **DRUG:** Finerenone Placebo

## Key facts

- **NCT ID:** NCT05254002
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-23
- **Primary completion:** 2025-03-14
- **Final completion:** 2025-03-14
- **Target enrollment:** 1664 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05254002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05254002, "A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05254002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*